Physician profile
Priti Pathak
NPI 1245321454
$751.38
in general payments reported to CMS, 2019-2025
14 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2022: $138 · 2023: $236 · 2024: $40.37 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.08 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $122.29 | 2022-2023 | Shingrix |
| Gilead Sciences, INC. | $115.86 | 2023 | Epclusa |
| Vanda Pharmaceuticals INC. | $107.61 | 2025 | Fanapt |
| Amgen INC. | $105.84 | 2022 | |
| Sunovion Pharmaceuticals INC. | $67.58 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.81 | 2025 | Caplyta |
| Allergan, INC. | $40.86 | 2019 | |
| Novo Nordisk INC | $40.42 | 2024-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $31.17 | 2024-2025 | |
| Lilly USA, LLC | $20.42 | 2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2023 | Gattex |
| Otsuka America Pharmaceutical, INC. | $14.84 | 2019 | |
| Neurelis, INC. | $14.48 | 2023 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priti Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.